A Phase II Trial of Cabozantinib (XL-184) (NSC-761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Nov 2016 Status changed from suspended to active, no longer recruiting.
- 16 Dec 2015 Status changed from recruiting to suspended as per ClinicalTrials.gov record.